What is HC Wainwright’s Estimate for ONCY FY2030 Earnings?

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Analysts at HC Wainwright lowered their FY2030 EPS estimates for shares of Oncolytics Biotech in a research note issued on Tuesday, May 26th. HC Wainwright analyst P. Trucchio now expects that the company will earn $0.14 per share for the year, down from their prior estimate of $0.18. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.20) per share.

Oncolytics Biotech (NASDAQ:ONCY) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03).

A number of other equities analysts have also commented on ONCY. Weiss Ratings upgraded shares of Oncolytics Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 8th. Wall Street Zen lowered shares of Oncolytics Biotech from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.50.

Oncolytics Biotech Price Performance

Oncolytics Biotech stock opened at $0.81 on Wednesday. The company has a market capitalization of $96.71 million, a PE ratio of -2.61 and a beta of 1.02. Oncolytics Biotech has a one year low of $0.33 and a one year high of $1.51. The business has a 50 day simple moving average of $0.94 and a 200 day simple moving average of $0.98.

Institutional Trading of Oncolytics Biotech

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC acquired a new stake in shares of Oncolytics Biotech in the first quarter valued at approximately $608,000. PFG Investments LLC increased its holdings in shares of Oncolytics Biotech by 131.0% in the first quarter. PFG Investments LLC now owns 52,900 shares of the company’s stock valued at $45,000 after purchasing an additional 30,000 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Oncolytics Biotech in the fourth quarter valued at approximately $68,000. Connective Capital Management LLC acquired a new stake in shares of Oncolytics Biotech in the fourth quarter valued at approximately $131,000. Finally, XTX Topco Ltd acquired a new stake in shares of Oncolytics Biotech in the fourth quarter valued at approximately $69,000. Institutional investors and hedge funds own 6.82% of the company’s stock.

About Oncolytics Biotech

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.